Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

@article{Hunger2013ChildrensOG,
  title={Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.},
  author={Stephen P Hunger and Mignon L Loh and James A. Whitlock and Naomi Joan Winick and William L Carroll and Meenakshi Devidas and Elizabeth A. Raetz},
  journal={Pediatric blood & cancer},
  year={2013},
  volume={60 6},
  pages={957-63}
}
Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 116 references

Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group (COG)

  • LA Mattano, J Nachman, M Devidas
  • Blood (ASH Annual Meeting abstracts)
  • 2008
Highly Influential
6 Excerpts

Improved survival for children and adolescents from 1990 to 2005: A report from the Children’s Oncology Group

  • SP Hunger, X Lu, M Devidas
  • J Clin Oncol 2012;30:1663–1669
  • 2012
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…